ID   RF-S1
AC   CVCL_A6KD
DR   Wikidata; Q107116737
RX   PubMed=2091939;
RX   PubMed=19003328;
CC   Group: Hybridoma fusion partner cell line.
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_6972 ! FO [Mouse myeloma]
HI   CVCL_0014 ! RPMI-8226
CA   Hybrid cell line
DT   Created: 20-05-21; Last updated: 21-03-23; Version: 3
//
RX   PubMed=2091939; DOI=10.1007/BF00151713;
RA   Kamei M., Hashizume S., Sugimoto N., Ozutsumi K., Matsuda M.;
RT   "Establishment of stable mouse/human-human hybrid cell lines producing
RT   large amounts of anti-tetanus human monoclonal antibodies with high
RT   neutralizing activity.";
RL   Eur. J. Epidemiol. 6:386-397(1990).
//
RX   PubMed=19003328; DOI=10.1023/A:1014049205434;
RA   Kawahara T., Ichikawa A., Katakura Y., Teruya K., Yoshida T.,
RA   Kikuchi M., Kamei M., Hashizume S., Shirahata S.;
RT   "Establishment of hybridomas producing cancer specific human
RT   antibodies from B cell line derived from PBL of a patient with adult T
RT   cell leukemia.";
RL   Cytotechnology 36:171-177(2001).
//